Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer.

Although statistically significant prognostic comparisons were limited by the small sample size in our internal cohort and MYC status was only evaluable at the time of recurrence, there did appear to be a numerical trend towards worse median survival with MYC amplification, as well as higher rates of recurrence, despite the majority of patients ultimately receiving immunotherapy in addition to chemoradiotherapy, conforming with previous observations 36 .

also in 337 other papers

Interestingly, the relative expression of T cell recruiting chemokines, immune checkpoints, genes associated with antigen presentation, and IFN-γ signaling showed a trend toward downregulation in MYC amplified tumors (Supplementary Fig. 2 ).

also in 18,965 other papers